Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
CASI CASI Pharmaceuticals, Inc. daily Stock Chart
CASI [NASD]
CASI Pharmaceuticals, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-0.48 Insider Own4.00% Shs Outstand98.77M Perf Week-3.52%
Market Cap244.22M Forward P/E- EPS next Y-0.31 Insider Trans122.43% Shs Float68.32M Perf Month-22.27%
Income-46.30M PEG- EPS next Q-0.08 Inst Own18.60% Short Float2.42% Perf Quarter15.66%
Sales7.50M P/S32.56 EPS this Y-48.00% Inst Trans2.58% Short Ratio4.26 Perf Half Y-30.31%
Book/sh0.71 P/B2.70 EPS next Y-3.30% ROA-43.20% Target Price- Perf Year-35.79%
Cash/sh0.43 P/C4.48 EPS next 5Y- ROE-59.20% 52W Range1.15 - 3.82 Perf YTD-37.86%
Dividend- P/FCF- EPS past 5Y12.10% ROI-64.30% 52W High-50.26% Beta0.96
Dividend %- Quick Ratio7.70 Sales past 5Y180.60% Gross Margin5.20% 52W Low65.22% ATR0.13
Employees125 Current Ratio7.90 Sales Q/Q- Oper. Margin- RSI (14)35.91 Volatility4.72% 5.95%
OptionableNo Debt/Eq0.00 EPS Q/Q0.00% Profit Margin- Rel Volume6.45 Prev Close1.92
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume388.53K Price1.90
Recom- SMA20-9.50% SMA50-20.05% SMA200-24.43% Volume143,606 Change-1.04%
Sep-22-16Initiated Maxim Group Buy $4
Oct-29-15Resumed H.C. Wainwright Buy $2.50 → $3
Jun-23-15Initiated H.C. Wainwright Buy $2.50
Jul-22-20 09:05AM  
CASI Pharmaceuticals Announces Pricing Of $38,000,000 Public Offering Of Common Stock
PR Newswire -14.80%
Jul-21-20 04:01PM  
CASI Pharmaceuticals Announces Proposed Public Offering Of Common Stock
PR Newswire
Jul-09-20 09:39AM  
Here's What CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Shareholder Ownership Structure Looks Like
Simply Wall St.
Jun-08-20 07:00AM  
CASI Pharmaceuticals Announces Submission Of Clinical Trial Application (IND) To Conduct Phase 1 Study For Anti-38 Monoclonal Antibody Program
PR Newswire
Jun-02-20 07:00AM  
CASI Pharmaceuticals To Present At The Jefferies 2020 Healthcare Conference
PR Newswire
May-31-20 05:38PM  
Do Hedge Funds Love CASI Pharmaceuticals Inc (CASI)?
Insider Monkey
May-25-20 06:14AM  
Wei-Wu He Is The Chairman & CEO of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) And They Just Picked Up 32% More Shares
Simply Wall St.
May-14-20 06:47AM  
Earnings Update: CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Just Reported And Analysts Are Boosting Their Estimates
Simply Wall St.
May-12-20 06:43AM  
Upgrade: Analysts Just Made A Notable Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts
Simply Wall St.
May-11-20 07:00AM  
CASI Pharmaceuticals Announces First Quarter 2020 Financial Results
PR Newswire
May-08-20 09:05AM  
CASI: A Change in Strategy
Zacks Small Cap Research
Apr-07-20 07:00AM  
CASI Pharmaceuticals To Present at 2020 Solebury Trout Virtual Investor Conference
PR Newswire -5.15%
Mar-31-20 07:05AM  
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Analysts Just Slashed This Year's Estimates
Simply Wall St.
Mar-29-20 08:08AM  
Insider Buying: The CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Chairman & CEO Just Bought US$1.1m Worth Of Shares
Simply Wall St.
Mar-16-20 07:00AM  
CASI Pharmaceuticals Announces Full Year 2019 Financial Results
PR Newswire -8.86%
Mar-02-20 06:03AM  
Did Changing Sentiment Drive CASI Pharmaceuticals's (NASDAQ:CASI) Share Price Down By 47%?
Simply Wall St.
Feb-21-20 07:46AM  
The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion
Benzinga
Feb-07-20 10:49AM  
Ligand (LGND) Q4 Earnings & Revenues Top Estimates, Stock Up
Zacks
Feb-04-20 07:51AM  
The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares
Benzinga
Jan-26-20 08:33AM  
What You Must Know About CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Beta Value
Simply Wall St.
Dec-20-19 05:27AM  
Have Insiders Been Buying CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Shares?
Simply Wall St.
Dec-03-19 09:00PM  
CASI Pharmaceuticals Announces China NMPA Approval Of CNCT19 (CD19 CAR-T) Clinical Trial Applications
PR Newswire
Nov-14-19 05:17AM  
CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Path To Profitability
Simply Wall St.
Nov-12-19 07:00AM  
CASI Pharmaceuticals Announces Third Quarter 2019 Financial Results
PR Newswire
Nov-07-19 07:00AM  
CASI Pharmaceuticals Enters Exclusive China Distribution License Agreement For Octreotide Long Acting Injectable (LAI) Microsphere For Neuroendocrine Cancers And Acromegaly
PR Newswire
Nov-06-19 09:33AM  
Ligand's (LGND) Q3 Earnings Miss Estimates, EPS View Down
Zacks
Sep-19-19 07:00AM  
CASI Pharmaceuticals Announces The Promotion Of Larry Zhang To President
PR Newswire
Sep-16-19 06:00AM  
China NMPA Accepts Clinical Trial Application For CASI's CD19 CAR-T-Product
PR Newswire
Sep-03-19 07:00AM  
CASI Pharmaceuticals, Inc. To Present At The 2019 H.C. Wainwright 21st Annual Global Investment Conference
PR Newswire
Aug-20-19 07:15PM  
Casi Pharmaceuticals Inc (CASI) CEO Wei-wu He Bought $64,000 of Shares
GuruFocus.com
Aug-19-19 12:22PM  
What Kind Of Shareholders Own CASI Pharmaceuticals, Inc. (NASDAQ:CASI)?
Simply Wall St.
Aug-16-19 10:20AM  
CASI: CASI launches Evomela - first commercial product
Zacks Small Cap Research
Aug-15-19 07:15PM  
Casi Pharmaceuticals Inc (CASI) CEO Wei-wu He Bought $507,200 of Shares
GuruFocus.com
Aug-12-19 03:03PM  
Rockville biopharma to sell first product on market in 28 years but not in the U.S.
American City Business Journals
07:00AM  
CASI Pharmaceuticals Announces Launch of EVOMELA® (melphalan for injection) in China
PR Newswire
Aug-09-19 07:00AM  
CASI Pharmaceuticals Announces Second Quarter and First Half 2019 Financial and Business Results
PR Newswire
Jul-31-19 10:44AM  
Ligand (LGND) Stock Down Despite Q2 Earnings & Sales Beat
Zacks
Jun-17-19 07:00AM  
CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy
PR Newswire
Jun-03-19 07:00AM  
CASI Pharmaceuticals To Present At The 2019 BIO International Convention
PR Newswire
May-20-19 09:45AM  
CASI: Making headway towards commercialization
Zacks Small Cap Research
May-15-19 07:00AM  
CASI Pharmaceuticals Announces First Quarter 2019 Financial and Business Results
PR Newswire
May-13-19 10:00AM  
CASI: Initiating coverage Leveraging pharmaceutical opportunities in China and beyond
Zacks Small Cap Research -5.36%
May-03-19 08:42AM  
Ligand (LGND) Q1 Earnings & Sales Fall Y/Y, Stock Down
Zacks
Apr-18-19 04:15PM  
INVESTOR ALERT: Monteverde & Associates PC Launches an Investigation of the Board of Directors and Officers
PR Newswire
Apr-17-19 07:00AM  
CASI Pharmaceuticals In-Licenses Exclusive Worldwide Rights to Novel Anti-CD38 Monoclonal Antibody Program From Black Belt Therapeutics
PR Newswire
Apr-02-19 07:00AM  
CASI Pharmaceuticals Announces The Appointment Of Wei-Wu He, Ph.D., Executive Chairman, To The Role Of Chief Executive Officer
PR Newswire -5.00%
Mar-29-19 07:00AM  
CASI Pharmaceuticals Announces Fourth Quarter And Full Year 2018 Financial Results And Business Results
PR Newswire -9.46%
Mar-13-19 07:00AM  
CASI Pharmaceuticals Announces Exclusive Distribution Partner For Melphalan Hydrochloride For Injection (EVOMELA®) In China
PR Newswire
Mar-07-19 07:00AM  
CASI Pharmaceuticals Announces China National Medical Products Administration (NMPA) Approval Of CTA To Conduct Registration Trial For MARQIBO®
PR Newswire
Feb-26-19 08:14AM  
When Will CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Turn A Profit?
Simply Wall St.
Feb-20-19 08:15AM  
Report: Developing Opportunities within Pure Storage, Flowers Foods, Cognex, CASI Pharmaceuticals, Ellie Mae, and Douglas Emmett Future Expectations, Projections Moving into 2019
GlobeNewswire
Feb-19-19 07:00AM  
CASI Pharmaceuticals Announces China National Medical Products Administration (NMPA) Approval Of CTA To Conduct Confirmatory Clinical Trial For ZEVALIN®
PR Newswire
Feb-06-19 07:00AM  
CASI Pharmaceuticals to Present at the BIO CEO & Investor Conference
PR Newswire
Dec-28-18 11:45AM  
These 4 Healthcare Stocks Are Heating Up
ACCESSWIRE
Dec-26-18 09:32AM  
Do Institutions Own Shares In CASI Pharmaceuticals, Inc. (NASDAQ:CASI)?
Simply Wall St. +7.23%
Dec-03-18 09:15AM  
The 4 Healthcare Stocks To Watch On Monday
ACCESSWIRE +5.31%
08:12AM  
CASI Pharmaceuticals Announces China Market Approval Of Melphalan Hydrochloride For Injection (Trademark: EVOMELA®)
PR Newswire
Nov-30-18 04:05PM  
Chinese biotech stocks hit by a double whammy, which means its time to buy
MarketWatch +10.74%
Nov-28-18 08:40AM  
Report: Exploring Fundamental Drivers Behind CASI Pharmaceuticals, Booking, Enstar Group, Madrigal Pharmaceuticals, Dermira, and Kaiser Aluminum New Horizons, Emerging Trends, and Upcoming Developments
GlobeNewswire
Nov-16-18 07:00AM  
CASI Pharmaceuticals To Build GMP Manufacturing Site In Wuxi, China
PR Newswire +16.48%
Nov-14-18 07:00AM  
CASI Pharmaceuticals Announces Third Quarter and First Nine Months 2018 Financial and Business Results
PR Newswire
Oct-24-18 08:00AM  
Todays Research Reports on Stocks to Watch: CASI Pharmaceuticals and Therapix Biosciences
ACCESSWIRE -15.63%
Oct-23-18 03:47PM  
Why CASI Pharmaceuticals Inc. Is Rocketing Higher Today
Motley Fool +20.96%
02:30PM  
3 Healthcare Stocks Trending Higher On News
ACCESSWIRE
07:05AM  
CASI Pharmaceuticals Acquires HBV ANDA from Laurus Labs Limited
PR Newswire
Oct-18-18 08:40AM  
Detailed Research: Economic Perspectives on Beacon Roofing Supply, Rowan Companies, CASI Pharmaceuticals, LivePerson, Impinj, and Tredegar What Drives Growth in Today's Competitive Landscape
GlobeNewswire
Oct-02-18 07:00AM  
CASI Pharmaceuticals Announces Appointment Of President To Its China Operations To Lead Commercialization
PR Newswire
Sep-28-18 07:00AM  
CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer
PR Newswire -9.50%
Sep-14-18 07:00AM  
CASI Pharmaceuticals Announces $48.5 Million Private Placement
PR Newswire
Aug-27-18 08:20AM  
Factors of Influence in 2018, Key Indicators and Opportunity within Steelcase, SecureWorks, Cleveland-Cliffs, Tredegar, Warrior Met Coal, and CASI Pharmaceuticals New Research Emphasizes Economic Growth
GlobeNewswire
Aug-14-18 07:00AM  
CASI Pharmaceuticals Announces Second Quarter And First Half 2018 Financial And Business Results
PR Newswire
Jul-05-18 07:43AM  
Benzinga's Daily Biotech Pulse: Realm Therapeutics To List On Nasdaq, CASI Pharma Added To Russell 2000 Index
Benzinga
Jul-03-18 01:05PM  
CASI Pharmaceuticals Added To Russell 2000®, 3000® And Microcap® Indexes
PR Newswire
Jun-25-18 08:00AM  
Report: Exploring Fundamental Drivers Behind Cabot Oil & Gas, Chesapeake Lodging Trust, CASI Pharmaceuticals, Peabody Energy, Alcoa, and Edwards Lifesciences New Horizons, Emerging Trends, and Upcoming Developments
GlobeNewswire
Jun-21-18 04:14PM  
Here's Why CASI Pharmaceuticals Rose as Much as 31.6% Today
Motley Fool
07:00AM  
CASI Pharmaceuticals Enters Strategic Partnering And Contract Manufacturing Agreement With Yiling Wanzhou International Pharmaceuticals For Entecavir And Cilostazol
PR Newswire
May-31-18 08:30AM  
Free Technical Insights on CASI Pharma and Three Other Biotech Stocks
ACCESSWIRE -5.65%
May-29-18 07:00AM  
CASI Pharmaceuticals To Present At The BIO International Convention
PR Newswire -5.89%
May-15-18 07:00AM  
CASI Pharmaceuticals Announces First Quarter 2018 Financial And Business Results
PR Newswire
May-07-18 07:30AM  
Detailed Research: Economic Perspectives on CASI Pharmaceuticals, Energy Transfer Partners, Cypress Semiconductor, Xcel Energy, Ironwood Pharmaceuticals, and KalVista Pharmaceuticals What Drives Growth in Today's Competitive Landscape
GlobeNewswire
May-02-18 12:01PM  
Harry Boxers four biotech stocks to watch today
MarketWatch +11.62%
Apr-30-18 04:47PM  
Can These Top-Performing Biotech Stocks Keep Climbing?
Motley Fool
Apr-16-18 07:40AM  
Blog Exposure - Enanta Pharma Announced Presentation of New Data for Core Inhibitor for Hepatitis B Virus and FXR Agonist EDP-305 for NASH
ACCESSWIRE
Apr-08-18 07:17AM  
What Stocks Perform Well in the Midst of a Trade War?
Motley Fool
Apr-06-18 04:23PM  
Here's Why CASI Pharmaceuticals Rose as Much as 23.4% Today
Motley Fool +13.98%
Apr-05-18 08:00AM  
CASI Pharmaceuticals Provides Update On EVOMELA®
PR Newswire
Apr-03-18 07:00AM  
CASI Pharmaceuticals To Present At The H.C. Wainwright Global Life Sciences Conference
PR Newswire +47.54%
Mar-29-18 07:00AM  
CASI Pharmaceuticals Announces Fourth Quarter And Full Year 2017 Financial Results
PR Newswire +9.45%
Mar-21-18 08:10AM  
Todays Research Reports on Trending Tickers: Arena Pharmaceuticals and CASI Pharmaceuticals
ACCESSWIRE
Mar-20-18 09:29AM  
CASI Pharmaceuticals Announces $50 Million Private Placement To Prepare Company For Commercialization In China
PR Newswire +21.81%
Mar-05-18 08:30AM  
Factors of Influence in 2018, Key Indicators and Opportunity within Cypress Semiconductor, Abaxis,Inc, Universal Health Services, CASI Pharmaceuticals, Energy Transfer Partners, and Arconic New Research Emphasizes Economic Growth
GlobeNewswire
Feb-09-18 07:00AM  
CASI Pharmaceuticals to Present at the BIO CEO & Investor Conference
PR Newswire
Jan-30-18 07:50AM  
Wired News CASI Pharma Purchased abbreviated new drug applications Portfolio from Sandoz
ACCESSWIRE
Jan-26-18 05:00PM  
CASI Pharmaceuticals Acquires ANDA Portfolio From Sandoz Inc. (Sandoz)
PR Newswire
Dec-01-17 07:00AM  
CASI Pharmaceuticals Announces Poster Presentation At The 2017 San Antonio Breast Cancer SymposiumTM (SABCS) On ENMD-2076 In Patients With Triple-Negative Breast Cancer (TNBC)
PR Newswire +18.24%
Nov-14-17 07:00AM  
CASI Pharmaceuticals Reports Third Quarter 2017 Financial Results
PR Newswire +8.37%
Nov-02-17 08:15AM  
Analysis: Positioning to Benefit within Tandem Diabetes Care, CASI Pharmaceuticals, SAExploration, Roka Bioscience, VirnetX, and PhaseRx Research Highlights Growth, Revenue, and Consolidated Results
GlobeNewswire
Oct-31-17 07:30AM  
CASI Pharmaceuticals, Capital Raise, Analysts Review, Product Development, and Guidance
ACCESSWIRE
Oct-13-17 10:00AM  
CASI Pharmaceuticals Announces $23.8 Million Registered Direct Offering Led By Existing Shareholders
PR Newswire
Sep-07-17 07:00AM  
CASI Provides Pipeline Development Update
PR Newswire
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprise CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma; CID-103, an anti-CD38 monoclonal antibody being for the treatment of patients with multiple myeloma; ZEVALIN, a CD20-directed radiotherapeutic antibody, to treat patients with NHL; and Thiotepa, a chemotherapeutic agent, which has multiple indications including use as a conditioning treatment for use prior to hematopoietic stem cell transplantation. In addition, the company offers MARQIBO, a microtubule inhibitor, approved by the FDA for the treatment of adult patients with Philadelphia chromosome-negative ALL; and Octreotide LAI formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumours, as well as developing a portfolio of 25 FDA-approved abbreviated new drug applications. It has licensing agreements with Black Belt Therapeutics Limited, Juventas Cell Therapy Ltd., and Pharmathen Global BV. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is based in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zhang LarryPresidentJul 22Buy1.9020,15338,29120,153Jul 24 04:05 PM
He Wei-WuChairman and CEOJul 22Buy1.901,200,0002,280,0007,532,347Jul 24 04:03 PM
He Wei-WuChairman and CEOJul 22Buy1.902,952,4265,609,6094,836,523Jul 24 04:03 PM
He Wei-WuChairman and CEOMay 20Buy2.3756,464133,8201,884,097May 21 05:01 PM
He Wei-WuChairman and CEOMay 19Buy2.0329,80160,4961,827,663May 21 05:01 PM
He Wei-WuChairman and CEOMay 18Buy2.02338,932684,6431,797,832May 19 05:55 PM
He Wei-WuChairman and CEOMay 15Buy1.82100,000182,0001,458,900May 19 05:55 PM
He Wei-WuChairman and CEOMar 27Buy2.086,88014,3101,358,900Mar 30 04:01 PM
He Wei-WuChairman and CEOMar 26Buy2.09328,095685,7191,352,020Mar 27 05:07 PM
He Wei-WuChairman and CEOMar 25Buy1.94196,398381,0121,023,925Mar 27 05:07 PM
He Wei-WuChairman and CEOMar 19Buy1.57234,488368,1466,332,347Mar 19 05:39 PM
He Wei-WuChairman and CEOMar 18Buy1.52501,322762,0096,097,859Mar 19 05:39 PM
He Wei-WuChairman and CEOMar 17Buy1.50264,192396,2885,596,537Mar 19 05:39 PM
He Wei-WuChief Executive OfficerAug 16Buy3.2020,00064,000827,527Aug 20 04:30 PM
He Wei-WuChief Executive OfficerAug 14Buy3.17160,000507,200807,527Aug 15 04:51 PM
open in yahoo | open in reuters | open in google